PE20141484A1 - Formulaciones peptidicas de liberacion controlada - Google Patents

Formulaciones peptidicas de liberacion controlada

Info

Publication number
PE20141484A1
PE20141484A1 PE2013002546A PE2013002546A PE20141484A1 PE 20141484 A1 PE20141484 A1 PE 20141484A1 PE 2013002546 A PE2013002546 A PE 2013002546A PE 2013002546 A PE2013002546 A PE 2013002546A PE 20141484 A1 PE20141484 A1 PE 20141484A1
Authority
PE
Peru
Prior art keywords
weight
preformulation
peptidic
formulations
refers
Prior art date
Application number
PE2013002546A
Other languages
English (en)
Inventor
Fredrik Tiberg
Catalin Nistor
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PE20141484A1 publication Critical patent/PE20141484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

SE REFIERE A UNA PREFORMULACION QUE COMPRENDE UNA MEZCLA DE BAJA VISCOSIDAD QUE COMPRENDE: a) 20-80% EN PESO DE UN DIACILGLICEROL Y/O UN TOCOFEROL; b) 20-80% EN PESO DE UNA FOSFATIDILCOLINA (PC); c) 5-20% EN PESO DE UN SOLVENTE MONO-ALCOHOLICO ORGANICO, BIOCOMPATIBLE; d) HASTA 20% EN PESO DE SOLVENTE POLAR TAL COMO AGUA, PROPILENGLICOL O MEZCLA DE LOS MISMOS; e) UN AGENTE ACTIVO PEPTIDICO TAL COMO UN ANALOGO DE SOMATOSTATINA; Y f) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO, EDTA O ACIDO CITRICO; DONDE LA RELACION DE COMPONENTES a:b ESTA DENTRO DEL RANGO 40:60 A 54:46; DONDE LA PREFORMULACION FORMA UNA ESTRUCTURA DE FASE CRISTALINA LIQUIDA LUEGO DEL CONTACTO CON FLUIDO ACUOSO EN EXCESO. SE REFIERE TAMBIEN A UN PROCESO PARA LA FORMACION DE DICHA PREFORMULACION, A DISPOSITIVOS Y KITS DE ADMINISTRACION
PE2013002546A 2011-05-25 2012-05-25 Formulaciones peptidicas de liberacion controlada PE20141484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25

Publications (1)

Publication Number Publication Date
PE20141484A1 true PE20141484A1 (es) 2014-10-31

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002546A PE20141484A1 (es) 2011-05-25 2012-05-25 Formulaciones peptidicas de liberacion controlada

Country Status (27)

Country Link
US (2) US11433120B2 (es)
EP (1) EP2714004B1 (es)
JP (2) JP6265888B2 (es)
KR (1) KR102066755B1 (es)
CN (2) CN108283619B (es)
AR (1) AR086577A1 (es)
AU (2) AU2012260821B2 (es)
BR (1) BR112013030104A8 (es)
CA (1) CA2836847C (es)
CL (1) CL2013003365A1 (es)
CO (1) CO6900117A2 (es)
CR (1) CR20130653A (es)
CU (1) CU20130158A7 (es)
DO (1) DOP2013000275A (es)
EA (1) EA036213B1 (es)
EC (1) ECSP13013107A (es)
GT (1) GT201300292A (es)
IL (1) IL229376B (es)
MX (1) MX361716B (es)
MY (1) MY177820A (es)
NI (1) NI201300127A (es)
PE (1) PE20141484A1 (es)
PH (1) PH12013502550A1 (es)
SG (1) SG194865A1 (es)
TW (1) TWI624271B (es)
WO (1) WO2012160213A1 (es)
ZA (1) ZA201309653B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
US9107904B2 (en) * 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
ES2834318T3 (es) * 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
WO2018060212A1 (en) * 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
DK3512495T3 (da) 2016-09-15 2022-12-05 Camurus Ab Formuleringer af prostacyklinanaloger
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
US20210169965A1 (en) * 2017-11-15 2021-06-10 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
AU2020282018A1 (en) 2019-05-29 2022-01-06 Camurus Ab Lipid-controlled release compositions
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
JP2024517204A (ja) * 2021-05-04 2024-04-19 カムルス エービー 神経内分泌腫瘍を治療するための組成物及び方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682091B1 (en) * 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
US8541400B2 (en) 2004-08-04 2013-09-24 Camurus Ab Compositions forming non-lamellar dispersions
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
JP5171262B2 (ja) * 2005-01-14 2013-03-27 カムルス エービー ソマトスタチン類似体製剤
US9757461B2 (en) * 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
ES2399645T3 (es) * 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
KR20140105527A (ko) * 2011-12-05 2014-09-01 카무러스 에이비 강력한 방출-조절된 펩티드 제형
ES2834318T3 (es) * 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
WO2018060212A1 (en) * 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt

Also Published As

Publication number Publication date
US11433120B2 (en) 2022-09-06
MX361716B (es) 2018-12-14
US20210308226A1 (en) 2021-10-07
CR20130653A (es) 2014-03-05
AR086577A1 (es) 2014-01-08
NI201300127A (es) 2014-02-25
WO2012160213A1 (en) 2012-11-29
ZA201309653B (en) 2016-05-25
MX2013013401A (es) 2013-12-12
AU2016202156B2 (en) 2018-03-22
AU2012260821B2 (en) 2016-01-07
IL229376A0 (en) 2014-01-30
DOP2013000275A (es) 2014-05-15
MY177820A (en) 2020-09-23
EA036213B1 (ru) 2020-10-14
JP2018076327A (ja) 2018-05-17
CN108283619B (zh) 2021-09-14
AU2016202156A1 (en) 2016-04-28
KR20140045438A (ko) 2014-04-16
CO6900117A2 (es) 2014-03-20
CN108283619A (zh) 2018-07-17
NZ617828A (en) 2016-11-25
JP2014520090A (ja) 2014-08-21
BR112013030104A2 (pt) 2016-09-20
CN103702662B (zh) 2018-07-20
EP2714004B1 (en) 2024-05-15
CU20130158A7 (es) 2014-04-24
JP6415673B2 (ja) 2018-10-31
BR112013030104A8 (pt) 2021-09-08
EP2714004A1 (en) 2014-04-09
GT201300292A (es) 2014-08-05
EA201391675A1 (ru) 2014-08-29
CA2836847A1 (en) 2012-11-29
ECSP13013107A (es) 2015-03-31
KR102066755B1 (ko) 2020-01-15
TW201249463A (en) 2012-12-16
US20140162944A1 (en) 2014-06-12
TWI624271B (zh) 2018-05-21
CN103702662A (zh) 2014-04-02
CA2836847C (en) 2021-06-29
PH12013502550B1 (en) 2015-08-10
PH12013502550A1 (en) 2015-08-10
CL2013003365A1 (es) 2014-07-25
JP6265888B2 (ja) 2018-01-24
SG194865A1 (en) 2013-12-30
IL229376B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PE20141484A1 (es) Formulaciones peptidicas de liberacion controlada
CU24400B1 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
AR106049A1 (es) Formulaciones de liberación controlada
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
GT201600060A (es) Formulaciones de espuma y aparatos para suminstro
PE20191713A1 (es) Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
CO2019012814A2 (es) Composición farmacéutica líquida estable
BR112014010812A2 (pt) anticongelante de gema de ovo de pato para criopreservação de sêmen de jumento e respectivo método de preparação
AR099097A1 (es) SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA
BR112017017643A2 (pt) formulação farmacêutica tópica
PH12014502614A1 (en) Somatostatin receptor agonist formulations
AR098351A1 (es) Sistema ruptor doble para reducir los daños en las formaciones durante la fracturación
CL2020000551A1 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales.
CL2018003793A1 (es) Reducción de deriva de pulverización.
CO2022000573A2 (es) Formulación agrícola
AR105691A1 (es) Método, composición y conjunto de elementos para tratar la disfunción eréctil
PE20131029A1 (es) Composicion pesticida
CO2018000526A2 (es) Concentrado que contiene alprostadil
PE20171305A1 (es) Formulaciones inyectables de paracetamol
CO2018000525A2 (es) Concentrado que contiene alprostadil
ECSP12012340A (es) Composicion pesticida
CL2019002843A1 (es) Formulación del inhibidor stat3.

Legal Events

Date Code Title Description
FG Grant, registration